Alturas Minerals Corp

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1997-01-01

Employees: 2

Market Cap: $476.1M

Website: http://www.altimmune.com

Introduction: Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune ...

Clinical Trials

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial)

Phase 2

Active, not recruiting

Conditions: Non-Alcoholic Steatohepatitis (NASH)

Interventions: Drug: Placebo
Drug: Pemvidutide

First Posted Date: 2023-08-14

Last Posted Date: 2024-09-30

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 190

Registration Number: NCT05989711

Locations: 🇵🇷
Altimmune Clinical Study Site, San Juan, Puerto Rico
🇺🇸
Altimmune Clinial Study Site, Tucson, Arizona, United States
🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

and more 9 locations

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Phase 2

Completed

Conditions: Obesity/Overweight

Interventions: Drug: ALT-801
Other: Placebo

First Posted Date: 2022-03-25

Last Posted Date: 2023-11-29

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 391

Registration Number: NCT05295875

Locations: 🇺🇸
Altimmune CTM, Saint George, Utah, United States
🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸
Cornell University, Joan and Sanford Weill Medical College, New York, New York, United States

and more 1 locations

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Phase 1

Completed

Conditions: Non-Alcoholic Fatty Liver Disease

Interventions: Drug: ALT-801
Other: Placebo

First Posted Date: 2022-03-23

Last Posted Date: 2023-07-27

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 64

Registration Number: NCT05292911

Locations: 🇺🇸
Wake Research CRCN, Las Vegas, Nevada, United States
🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Diagnostics Research Group, San Antonio, Texas, United States

and more 8 locations

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: ALT-801
Other: Placebo

First Posted Date: 2021-11-26

Last Posted Date: 2023-08-14

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 55

Registration Number: NCT05134662

Locations: 🇺🇸
Altimmune CTM, Tomball, Texas, United States

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Phase 1

Completed

Conditions: Non-Alcoholic Fatty Liver Disease

Interventions: Drug: ALT-801
Other: Placebo

First Posted Date: 2021-08-16

Last Posted Date: 2023-07-27

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 95

Registration Number: NCT05006885

Locations: 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Pinnacle Research, San Antonio, Texas, United States
🇺🇸
Diagnostics Research Group, San Antonio, Texas, United States

and more 10 locations

ALT-801 DDI Study in Healthy Volunteers

Phase 1

Completed

Conditions: NASH - Nonalcoholic Steatohepatitis

Interventions: Drug: ALT-801
Drug: Ethinylestradiol and Levonorgestrel
Drug: Metformin
Drug: Warfarin
Drug: Atorvastatin
Drug: Digoxin

First Posted Date: 2021-07-22

Last Posted Date: 2022-12-08

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 40

Registration Number: NCT04972396

Locations: 🇦🇺
Q-Pharm, Herston, Queensland, Australia
🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Phase 2

Terminated

Conditions: Hepatitis B, Chronic

Interventions: Biological: HepTcell
Drug: Placebo

First Posted Date: 2020-12-28

Last Posted Date: 2024-05-29

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 87

Registration Number: NCT04684914

Locations: 🇬🇧
Queens Medical Center, Nottingham, United Kingdom
🇬🇧
St. Georges University of London, London, United Kingdom
🇪🇸
Hospital Universitario La Paz, Madrid, Spain

and more 18 locations

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: AdCOVID
Other: Placebo

First Posted Date: 2020-12-22

Last Posted Date: 2023-08-14

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 92

Registration Number: NCT04679909

Locations: 🇺🇸
AGA Clinical Trials, Hialeah, Florida, United States
🇺🇸
Clinical Trials of Texas, San Antonio, Texas, United States
🇺🇸
Optimal Research, Austin, Texas, United States

ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

Phase 1

Completed

Conditions: NASH - Nonalcoholic Steatohepatitis

Interventions: Drug: ALT-801
Other: Placebo

First Posted Date: 2020-09-23

Last Posted Date: 2021-11-10

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 100

Registration Number: NCT04561245

Locations: 🇦🇺
Nucleus Networks, Herston, Queensland, Australia

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Phase 2

Terminated

Conditions: Coronavirus Infection

Interventions: Biological: NasoVAX
Other: Placebo

First Posted Date: 2020-06-22

Last Posted Date: 2022-04-04

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 48

Registration Number: NCT04442230

Locations: 🇺🇸
Cedar Crosse Research Center, Chicago, Illinois, United States
🇺🇸
Miami Dade Medical Research Institute, Miami, Florida, United States
🇺🇸
Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy